Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 43, 2012, Pages

  McAuliffe, Shannon M ^a   Morgan, Stefanie L ^a   Wyant, Gregory A ^a   Tran, Lieu T ^a   Muto, Katherine W ^a   Chen, Yu Sarah ^a   Chin, Kenneth T ^a   Partridge, Justin C ^a   Poole, Barish B ^a   Cheng, Kuang Hung ^a   Daggett, John ^a   Cullen, Kristen ^b   Kantoff, Emily ^c   Hasselbatt, Kathleen ^a   Berkowitz, Julia ^a   Muto, Michael G ^a,c   Berkowitz, Ross S ^a,c   Aster, Jon C ^a   Matulonis, Ursula A ^c   Dinulescu, Daniela M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CELL SIGNALING TECHNOLOGY   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Isobologram and combination index analysis; Notch3 expression patterns; Platinum induced DNA damage response; Synergistic cytotoxic effects for GSI cisplatin combination therapy; Tumor models

Indexed keywords

CISPLATIN; GAMMA SECRETASE INHIBITOR; NOTCH RECEPTOR; SMALL INTERFERING RNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; ERADICATION THERAPY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HUMAN; HUMAN CELL; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL EXPANSION;

EID: 84867919330     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1206400109     Document Type: Article

References (35)

1. Permuth-Wey J, Sellers TA (2009) Epidemiology of ovarian cancer. Methods Mol Biol 472:413-437.
2. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519-2529.
3. Ozols RF, et al. (2004) Focus on epithelial ovarian cancer. Cancer Cell 5:19-24. (Pubitemid 38121593)
4. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC (2001) Ovarian surface epithelium: Biology, endocrinology, and pathology. Endocr Rev 22:255-288. (Pubitemid 32458162)
5. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105-111. (Pubitemid 33041634)
6. Campbell LL, Polyak K (2007) Breast tumor heterogeneity: Cancer stem cells or clonal evolution? Cell Cycle 6:2332-2338. (Pubitemid 350058682)
7. Shackleton M, Quintana E, Fearon ER, Morrison SJ (2009) Heterogeneity in cancer: Cancer stem cells versus clonal evolution. Cell 138:822-829.
8. Shipitsin M, et al. (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11:259-273. (Pubitemid 46349843)
9. Mani SA, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704-715. (Pubitemid 351636299)
10. Marotta LL, Polyak K (2009) Cancer stem cells: A model in the making. Curr Opin Genet Dev 19:44-50.
11. Polyak K, Hahn WC (2006) Roots and stems: Stem cells in cancer. Nat Med 12:296-300. (Pubitemid 43355075)
12. Szotek PP, et al. (2006) Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA 103:11154-11159. (Pubitemid 44156488)
13. Alvero AB, et al. (2009) Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 8:158-166.
14. Moserle L, et al. (2008) The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res 68:5658-5668.
15. Zhang S, et al. (2008) Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68:4311-4320.
16. Wei X, et al. (2010) Mullerian inhibiting substance preferentially inhibits stem/ progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc Natl Acad Sci USA 107:18874-18879.
17. Meirelles K, et al. (2012) Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proc Natl Acad Sci USA 109:2358-2363.
18. Bookman MA, et al. (1996) Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group. J Clin Oncol 14:1895-1902. (Pubitemid 26185464)
19. McGuire WP, et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6.
20. Armstrong DK, et al.Gynecologic Oncology Group (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43. (Pubitemid 43048949)
21. Walker JL, et al. (2006) Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study. Gynecol Oncol 100:27-32. (Pubitemid 41815045)
22. Gupta PB, et al. (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138:645-659.
23. Choi JH, et al. (2008) Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res 68:5716-5723.
24. Park JT, et al. (2006) Notch3 geneamplification in ovarian cancer. Cancer Res 66:6312-6318.
25. Shih IeM, Wang TL (2007) Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 67:1879-1882.
26. Dinulescu DM, et al. (2005) Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11:63-70. (Pubitemid 40215839)
27. Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615.
28. Sorenson CM, Barry MA, Eastman A (1990) Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. J Natl Cancer Inst 82:749-755. (Pubitemid 20159274)
29. Nicioli da Silva G, et al. (2010) Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine. Exp Biol Med 235:814-824.
30. Wang S, et al. (2012) Molecular imaging of p53 signal pathway in lung cancer cell cycle arrest induced by cisplatin. Mol Carcinog, 10.1002/mc.21930.
31. Hosonuma S, et al. (2011) Clinical significance of side population in ovarian cancer cells. Hum Cell 24:9-12.
32. Park JT, et al. (2010) Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol 177:1087-1094.
33. Matulonis UA, et al. (2011) High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PLoS ONE 6:e24433.
34. Cruet-Hennequart S, et al. (2009) Characterization of the effects of cisplatin and carboplatin on cell cycle progression and DNA damage response activation in DNA polymerase eta-deficient human cells. Cell Cycle 8:3039-3050.
35. Wu Y, et al. (2010) Therapeutic antibody targeting of individual Notch receptors. Nature 464:1052-1057.